10x Genomics, Inc. (TXG) is a Medical - Healthcare Information Services company in the Healthcare sector, currently trading at $24.80. It has a SharesGrow Score of 40/100, indicating a mixed investment profile with 2 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of TXG = $862.61 (+3378.3% from the current price, the stock appears undervalued). Analyst consensus target is TXG = $21 (-15.3% upside).
Valuation: TXG trades at a trailing Price-to-Earnings (P/E) of -65.8 (S&P 500 average ~25) with a forward Price/Earnings-to-Growth (PEG) of 2.29.
Financials: revenue is $643M, +7.9%/yr average growth. Net income is $44M (loss), growing at +17%/yr. Net profit margin is -6.8% (negative). Gross margin is 69.1% (-7.6 pp trend).
Balance sheet: total debt is $158M against $796M equity (Debt-to-Equity (D/E) ratio 0.2, conservative). Current ratio is 4.46 (strong liquidity). Debt-to-assets is 15.1%. Total assets: $1.0B.
Analyst outlook: 10 / 22 analysts rate TXG as buy (45%) — mixed sentiment.
SharesGrow 7-Criteria breakdown: Value 29/100 (Fail), Growth 73/100 (Pass), Past 0/100 (Fail), Health 100/100 (Pass), Moat 55/100 (Partial), Future 16/100 (Fail), Income 10/100 (Fail).
